Earnings Feed
Start Free
Home/Filings/4/0000899243-22-013342
4//SEC Filing

Appelbaum Kevin J 4

Accession 0000899243-22-013342

CIK 0001832415other
View on SEC.govCompany Profile

Filed

Apr 3, 8:00 PM ET

Accepted

Apr 4, 4:27 PM ET

Size

10.9 KB

Accession

0000899243-22-013342

Insider Transaction Report

Form 4
Period: 2022-03-31
Better Therapeutics, Inc.BTTX
Appelbaum Kevin J
DirectorChief Executive Officer10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-04-01+235,000→ 235,000 total
    Exercise: $1.97Exp: 2032-03-31→ Common Stock (235,000 underlying)
  • Purchase

    Common Stock

    2022-03-31$1.97/sh+2,500$4,921→ 6,250 total
Holdings

  • Common Stock

    (indirect: By Trust)
    2,406,719
Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated 5/16/2020, as amended
10% Owner
Transactions
  • Purchase

    Common Stock

    2022-03-31$1.97/sh+2,500$4,921→ 6,250 total
  • Award

    Stock Option (Right to Buy)

    2022-04-01+235,000→ 235,000 total
    Exercise: $1.97Exp: 2032-03-31→ Common Stock (235,000 underlying)
Holdings

  • Common Stock

    (indirect: By Trust)
    2,406,719
Footnotes (3)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.96 to $1.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F2]These shares are owned directly by Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated May 16, 2020, as amended (the "Trust"), and indirectly by Mr. Appelbaum as trustee of the Trust. Mr. Appelbaum is an officer, director and ten percent owner of the Issuer.
  • [F3]The stock option vests as to 1/4 of the shares subject to the stock option on April 1, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on April 1, 2022.

Documents

1 file

Issuer

Better Therapeutics, Inc.

CIK 0001832415

→
Entity typeother

Related Parties

1
  • filerCIK 0001547557

Filing Metadata

Form type
4
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 4:27 PM ET
Size
10.9 KB
View on SEC.gov